Jazz Pharmaceuticals plc reported $4.60B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.60B (to Q2 2026). Net income: $941M, trailing twelve months to Q2 2026. Free cash flow: $1.59B, trailing twelve months to Q2 2026. Operating margin: 20%, trailing twelve months to Q2 2026.

JAZZJazz Pharmaceuticals plc

Healthcare

$218.41+70% 1Y

$218.41

$127.0052 weeks$261.72

JAZZ as reported

Jazz Pharmaceuticals plc reported $4.60B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed.

$4.60B

Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before

Net income: $941M
Net income · −332% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.59B
Free cash flow · +26% year on year · trailing twelve months to Q2 2026
Operating margin: 20%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for JAZZ, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.60B	+13%	Q2 2026
Net income	$941M	−332%	Q2 2026
EPS	$14.63	−315%	Q2 2026
Gross margin	93%	n/a	Q4 2020 · 22 quarters behind
Operating margin	20%	n/a	Q2 2026
Net margin	21%	n/a	Q2 2026
ROE	0.67%	n/a	Q2 2026
ROA	0.61%	n/a	Q2 2026
ROIC	0.01%	n/a	Q2 2026
Free cash flow	$1.59B	+26%	Q2 2026
P/E	14.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.